Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis Halts COVID-19 HCQ Study | Contract Pharma

What are you searching for?

Sign in
Breaking News

Novartis Halts COVID-19 HCQ Study

Discontinues hydroxychloroquine clinical trial based on slow enrollment, no safety issues have been reported or efficacy conclusions made.

By: Contract Pharma

Contract Pharma Staff

Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made trial completion infeasible.
 
The Swiss pharma giant said recruitment challenge facing the HCQ trial wouldn’t allow its clinical team to be able to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with COVID-19.
 
No safety issues have been reported, and there are no conclusions on efficacy from the study.
 
Novartis said it will continue to provide supply of HCQ for ongoing investigator-initiated trials (IITs) and upon government requests, as appropriate, where certain conditions are met and the medicine is used in accordance with a nationally endorsed treatment protocol. Researchers at Novartis continue to monitor ongoing guidance from health authorities on the further study of HCQ for COVID-19, as well as the decision by the U.S. FDA to stop the emergency use authorization of HCQ for COVID-19 treatment.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters